Anixa Biosciences, Inc. (ANIX) financial statements (2020 and earlier)

Company profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:6657376
Cash and cash equivalents3333243
Short-term investments3224123
Other undisclosed cash, cash equivalents, and short-term investments  0(0)(0)(0)(0)
Receivables00    0
Other undisclosed current assets0000000
Total current assets:6667376
Noncurrent Assets
Operating lease, right-of-use asset0 
Property, plant and equipment0000000
Intangible assets, net (including goodwill) (2)(2)(1)(1)(1)(0)
Intangible assets, net (excluding goodwill) (2)(2)(1)(1)(1)(0)
Other undisclosed noncurrent assets 223333
Total noncurrent assets:0012223
TOTAL ASSETS:6669699
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111001
Accounts payable0110001
Accrued liabilities1110000
Employee-related liabilities    0 0
Debt0      
Other undisclosed current liabilities     01
Total current liabilities:1111012
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0 
Other undisclosed noncurrent liabilities    443
Total noncurrent liabilities:0   443
Total liabilities:1111545
Stockholders' equity
Stockholders' equity attributable to parent5558154
Preferred stock    000
Common stock0000002
Additional paid in capital190187175164152151146
Accumulated deficit(184)(182)(170)(156)(151)(146)(145)
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)    
Total stockholders' equity:5558154
TOTAL LIABILITIES AND EQUITY:6669699

Income statement (P&L) ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Revenues0010094
Revenue, net 094
Cost of revenue(1)(0)(2)(0)(0)  
Gross profit:(1)0(1)0(0)94
Operating expenses(9)(12)(13)(6)(4)(10)(12)
Other undisclosed operating income0    03
Operating loss:(10)(12)(14)(6)(5)(1)(5)
Nonoperating income0000002
Investment income, nonoperating000000(0)
Debt instrument, convertible, beneficial conversion feature      2
Interest and debt expense   1(1)(0)(4)
Other undisclosed loss from continuing operations before equity method investments, income taxes      (2)
Net loss:(9)(12)(14)(5)(5)(1)(10)
Net income attributable to noncontrolling interest000    
Other undisclosed net loss attributable to parent   (2)   
Net loss available to common stockholders, diluted:(9)(12)(14)(7)(5)(1)(10)

Comprehensive Income ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Net loss:(9)(12)(14)(5)(5)(1)(10)
Comprehensive loss:(9)(12)(14)(5)(5)(1)(10)
Comprehensive income, net of tax, attributable to noncontrolling interest000    
Comprehensive loss, net of tax, attributable to parent:(9)(12)(14)(5)(5)(1)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: